Clinically relevant end points and new drug approvals for myeloma.

摘要: This manuscript summarizes the recommendations of American Society Hematology/US Food and Drug Administration Workshop on Clinical Endpoints in Multiple Myeloma, which brought together clinical investigators multiple myeloma, United States Administration, pharmaceutical companies, patient advocates other concerned scientists physicians to provide guidance, consensus consistency definition clinically relevant end points expedite new drug approvals for myeloma appropriate trial design settings. will therefore be a most valuable resource framework strategies more rapid approval myeloma.